Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 17/20 | 0.80 |
| ▸ | FLT3 | P36888 | 5/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | CDK7 | P50613 | 2/20 | 0.56 |
| ▸ | BLK | P51451 | 2/20 | 0.56 |
| ▸ | CCNH | P51946 | 2/20 | 0.56 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427792 | 0.89 | IRAK4 (1.00) | IRAK4FLT3MAPK8IRAK1LCK | |
| SCHEMBL22145804 | 0.88 | IRAK4 (1.00) | IRAK4FLT3IRAK1LCKRET | |
| SCHEMBL19900082 | 0.86 | FLT3 (1.00) | IRAK4FLT3IRAK1 | |
| SCHEMBL24828770 | 0.86 | IRAK4 (0.71) | IRAK4FLT3MAPK8MAPK9IRAK1 | |
| SCHEMBL23683355 | 0.85 | IRAK4 (0.70) | IRAK4FLT3MAPK8MAPK9IRAK1 | |
| SCHEMBL23683353 | 0.85 | IRAK4 (0.70) | IRAK4FLT3MAPK8MAPK9IRAK1 | |
| SCHEMBL22145801 | 0.85 | IRAK4 (1.00) | IRAK4FLT3MAPK8IRAK1LCK | |
| SCHEMBL26357485 | 0.85 | IRAK4 (0.63) | IRAK4FLT3MAPK8MAPK9 | |
| SCHEMBL27361717 | 0.82 | IRAK4 (0.59) | IRAK4FLT3IRAK1LCKRET | |
| SCHEMBL26463492 | 0.80 | IRAK4 (0.77) | IRAK4FLT3MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | IRAK1, IRAK4, FLT3 | IRAK4 2/4885FLT3 3/4885MAPK8 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.